ERBB2 and non-small cell lung carcinoma: In the Drug Rediscovery Protocol (DRUP) trial, trastuzumab + pertuzumab demonstrated limited activity in patients with heavily pre-treated HER2-positive NSCLC (ORR 8.3%; DCR 38.0%; PFS 4.0 months; OS 10.0 months) [33].